Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 6/20 | 0.61 |
| ▸ | SHMT1 | P34896 | 5/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255697 | 0.93 | SHMT2 (0.66) | SHMT2SHMT1EGLN1LMNAHPGD | |
| SCHEMBL20255787 | 0.81 | SHMT1 (0.81) | SHMT2SHMT1LMNAHPGDKDM4E | |
| SCHEMBL20255640 | 0.81 | SHMT2 (0.64) | SHMT2SHMT1LMNAHPGDKDM4E | |
| SCHEMBL20255875 | 0.81 | SHMT2 (0.60) | SHMT2SHMT1EGLN1LMNAKDM4E | |
| SCHEMBL31578642 | 0.81 | SHMT2 (0.55) | SHMT2SHMT1EGLN1LMNAHPGD | |
| SCHEMBL21560186 | 0.81 | SHMT1 (0.54) | SHMT2SHMT1LMNAKDM4EALDH1A1 | |
| SCHEMBL20255445 | 0.80 | SHMT2 (0.74) | SHMT2SHMT1LMNAHPGDKDM4E | |
| SCHEMBL31578929 | 0.80 | SHMT2 (0.71) | SHMT2SHMT1EGLN1LMNAHPGD | |
| SCHEMBL20255597 | 0.80 | SHMT1 (0.89) | SHMT2SHMT1LMNAHPGDKDM4E | |
| SCHEMBL20255444 | 0.80 | SHMT2 (0.68) | SHMT2SHMT1LMNAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885EGLN1 250/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | SHMT2 2/4885SHMT1 1/4885EGLN1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.